Cara Therapeutics (CARA) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cara Therapeutics Reports Second Quarter 2016 Financial Results
August 4, 2016 4:02 PM EDTResumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative painÂ
Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis patients with uremic pruritusÂ
Initiation of Phase 2b trial of Oral CR845 in osteoarthritis patients expected in Q3, 2016
Conference call today at 4:30 p.m. ET
STAMFORD, Conn., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively... More
